---
title: "Weekly Recap | Maxlinear -9.22%, consensus target below spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/301469285.md"
description: "Maxlinear fell 9.22% this week to $96.16, sharply underperforming the S&P 500’s +1.15% and lagging the benchmark by about 10.37 percentage points. The week opened firm with gains on Monday and Tuesday, touched an intra-week high of $113.13 on Wednesday, then sold off hard on Thursday with a low of $93.21. Friday pushed the low further to $91.65 before settling at $96.16. Weekly amplitude was 20.37%, with average daily volume around 3.01m shares."
datetime: "2026-10-10T07:09:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/301469285.md)
  - [en](https://longbridge.com/en/news/301469285.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/301469285.md)
generator: "portal-rs"
---

# Weekly Recap | Maxlinear -9.22%, consensus target below spot

## The Week

Maxlinear fell 9.22% this week to $96.16, sharply underperforming the S&P 500’s +1.15% and lagging the benchmark by about 10.37 percentage points. The week opened firm with gains on Monday and Tuesday, touched an intra-week high of $113.13 on Wednesday, then sold off hard on Thursday with a low of $93.21. Friday pushed the low further to $91.65 before settling at $96.16. Weekly amplitude was 20.37%, with average daily volume around 3.01m shares. The stock now sits near the lower end of its recent trading range.

## Key Events

Maxlinear’s own news and the sector backdrop crossed paths this week. On Tuesday the firm introduced Topaz, an AI-ready PON HGU chip for 10G and beyond. The same day brought broader industry chatter about fringe players pivoting or risking irrelevance in the AI build-out. By Friday, intraday reports noted an 11.18% slide and suggested the Puma 9 positives failed to offset market concerns. Meanwhile optical communication stocks rallied, with Lumentum’s optical component capacity reportedly sold out through 2029. Maxlinear did not participate in that move, finishing the week relatively weak against peers.

## Analyst Ratings

Among 11 covering institutions, 6 rate the stock buy, 1 rate it overweight, and 4 rate it hold; none carry underweight or sell ratings. The consensus recommendation is buy, with a consensus target of $94.55, slightly below the latest traded price. The target range is wide, from $40.00 on the low end to $125.00 on the high end. Within the semiconductor manufacturers industry group of 77 names, the stock ranks 34th.

## The Week Ahead

The macro calendar dominates early next week. US CPI and core CPI land on Wednesday, 14 October, with consensus looking for headline CPI around 3.7% and core CPI around 2.5%. Those prints will steer rate expectations. On Thursday, 22 October, Maxlinear reports fiscal Q3 2026 results after the close; estimates point to EPS of about $0.16 and revenue of about $210m. That release is the key test for this week’s pullback and the wide analyst spread.

## In Short

The week’s tension is clear: analyst ratings still favour buy and overweight, yet the consensus target sits roughly at spot and the target range is unusually wide. Latest-session flows show large-lot buyers, but the stock still fell on heavy volume during the week. The market is pricing AI-adjacent edge names more sceptically, and Maxlinear failed to catch the optical communication rally. CPI and the 22 October earnings release will shape the next directional cue.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [MXL.US](https://longbridge.com/en/quote/MXL.US.md)

## Related News & Research

- [MaxLinear Stock In Focus After New AI Optics Power Chip Launch](https://longbridge.com/en/news/305513238.md)
- [MaxLinear Unveils Jeju™ Custom PMIC, Engineered for Peak Efficiency with 1.6T Optical DSPs | MXL Stock News](https://longbridge.com/en/news/304971557.md)
- [What Does AbbVie (ABBV) Gain From Progress In Its Migraine Pipeline Deal?](https://longbridge.com/en/news/305521964.md)
- [Cadence Design Systems (CDNS) Launches New AI Tools, Is It Still 20% Undervalued?](https://longbridge.com/en/news/305521888.md)
- [CVS plans major breakup, separating 9,000 pharmacies as shares plunge](https://longbridge.com/en/news/305520089.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**